Alice Gottlieb
Overview
Explore the profile of Alice Gottlieb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
2571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armstrong A, Fried R, Koo J, Gottlieb A, Jackson A
J Drugs Dermatol
. 2023 Oct;
22(10):994-1000.
PMID: 37801526
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indicated for the treatment of moderate-to-severe plaque...
2.
Srinivasan D, Gottlieb A
J Drugs Dermatol
. 2023 Mar;
22(3):297-299.
PMID: 36877872
Erythema dyschromicum perstans (EDP) is a rare cutaneous disorder in which patients develop gray or blue-brown macules or patches on their bodies.1 This condition does not appear to have a...
3.
Yousif J, Babalola F, Campbell C, Gottlieb A, Vargas J, Mitchell K
J Drugs Dermatol
. 2023 Feb;
22(2):223-225.
PMID: 36745373
Objective: To evaluate the synergistic effect of a fixed-combination topical lotion composed of halobetasol propionate 0.01% and tazarotene 0.045% in the treatment of palmoplantar psoriasis. Methods: This was an open-label...
4.
Zagona-Prizio C, Yousif J, Grant C, Mehta M, Rosmarin D, Silverberg N, et al.
J Drugs Dermatol
. 2022 Aug;
21(8):867-874.
PMID: 35946973
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization founded in 2013. It is composed of researchers and stakeholders who work to develop evidenced-based outcome measures to enhance research...
5.
Menter A, Cohen S, Kay J, Strand V, Gottlieb A, Hanauer S, et al.
Am J Clin Dermatol
. 2022 Aug;
23(5):719-728.
PMID: 35934770
Background: BI 695501 is an FDA-approved biosimilar to adalimumab reference product (RP). VOLTAIRE-X was a randomized clinical trial to assess outcomes with a biosimilar monoclonal antibody in line with the...
6.
Babalola F, Chima M, Jobarteh R, Gottlieb A
J Drugs Dermatol
. 2022 Mar;
21(3):313-314.
PMID: 35254754
Perifolliculitis capitis abscedens et suffodiens or dissecting cellulitis (DC) is a rare and chronic disease with a predilection for the occipital, vertex, and parietal scalp. DC is characterized by multinodular...
7.
Babalola F, Moattari C, Berman B, Bhatia N, Goldberg L, Gottlieb A, et al.
J Drugs Dermatol
. 2022 Feb;
21(2):128-134.
PMID: 35133114
This is a report of the survey results from the International Dermatology Outcome Measures (IDEOM) actinic keratosis (AK) workgroup. The purpose of the survey was to compile a list of...
8.
Mease P, Chohan S, Fructuoso F, Luggen M, Rahman P, Raychaudhuri S, et al.
Ann Rheum Dis
. 2021 May;
80(9):1147-1157.
PMID: 33985942
Objectives: To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). Methods: In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active...
9.
Mease P, Gladman D, Deodhar A, McGonagle D, Nash P, Boehncke W, et al.
RMD Open
. 2020 Jul;
6(2).
PMID: 32665433
Objective: To evaluate the effect of guselkumab on enthesitis and dactylitis in a phase II trial of patients with active psoriatic arthritis (PsA). Methods: This was a phase II, randomised,...
10.
Gottlieb A, Lebwohl M, Liu C, Israel R, Jacobson A
Am J Clin Dermatol
. 2020 Mar;
21(3):421-430.
PMID: 32207067
Background: Brodalumab is a fully human anti-interleukin-17 receptor A monoclonal antibody efficacious for the treatment of adults with moderate-to-severe plaque psoriasis. Objective: This study summarizes malignancy rates in psoriasis clinical...